Results from a post hoc analysis of the Spartan Phase III study of apalutamide showed that regardless of genetic subclass, treatment significantly improved the metastasis-free survival of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

The COVID-19 pandemic has changed the format of this year’s ASCO Annual Meeting. The conference ran from 29 – 31 May under the theme "Unite and Conquer: Accelerating Progress Together."

Three new therapeutic agents for the treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC), Apalutamid, Darolutamid and Enzalutamid, have recently been FDA approved.

The first results from the CheckMate 9LA trial – a randomized trial investigating the combination of a limited cause of chemotherapy together with nivolumab and ipilimumab as first line treatment for patients with advanced non small cell lung cancer.

In this ASCO podcast episode, Dr. David Fajgenbaum, American immunologist and author, tells about his involvement in finding a cure for the rare Castleman's disease.

Prostatakreft og osteoporose

I de mer enn 4300 danske menn som er diagnostisert med prostatakreft årlig, er kastrering en vanlig form for behandling. Kastrering er dermed gjort for omtrent en av tre med prostatakreft, og det er vanligvis gitt av kurativ strålebehandling. Menn som er medisinsk eller kirurgisk kastrert bør systematisk undersøkes for osteoporose og, om nødvendig, behandlet for dette, primært for å forhindre utvikling av osteoporose-relaterte brudd som ellers kan ha alvorlige konsekvenser.